ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1441

Factors Associated with the Evolution of Degenerative Spinal Lesions in Axial Spondyloarthritis: 10-Year Follow-up of the DESIR Cohort

Laura Pina Vegas1, Sofia Ramiro2, Miranda van Lunteren3, Damien Loeuille4, Esther Newsum5, Caroline Morizot6, Floris van Gaalen7, Alain SARAUX8, Pascal Claudepierre9, Antoine Feydy10, Desiree van der Heijde11 and Monique Reijnierse1, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center, Bunde, Netherlands, 3Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, 4Phd, Nancy Vandoeuvre, Lorraine, France, 5Nij Smellinghe, Drachten, Netherlands, 6Nancy University hospital, Nancy, France, 7LUMC, Leiden, Zuid-Holland, Netherlands, 8CHU Brest, Brest, France, 9CHU Henri Mondor, AP-HP/EpiDermE, UPEC, Créteil, France, 10CHU Cochin, AP-HP, Paris, France, 11Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands

Meeting: ACR Convergence 2024

Keywords: Imaging, Magnetic resonance imaging (MRI), Osteoarthritis, spondyloarthritis, X-ray

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Radiographs and MRI are both used to diagnose axial spondyloarthritis (axSpA) but they also provide information about morphological and even biomechanical changes in the spinal components. The natural course of degenerative lesions (DLs) in the spine over a long period of observation has not been established in a large group of patients with axSpA. Moreover, it is not well-known which factors are associated with faster progression. Our aim was to investigate the evolution of spinal DLs in axSpA patients over 10 years (10Y) and the factors associated with progression.

Methods: Cervical and lumbar spine radiographs and whole spine MRI at baseline, 5Y and 10Y of patients diagnosed with axSpA in the DESIR cohort were assessed for DLs by three central readers blinded to timepoint and to clinical, laboratory or any other imaging information1. Patients with available imaging (radiographs or MRI) at ≥1 time point were included. DLs were defined at patient level and, for descriptive purposes, in consensus across central readers (≥2 out of 3 readers or average, as appropriate). To assess progression of DLs of both imaging modalities (Table 1) over time, we used multilevel generalised estimating equation (GEE) models considering individual reader data and exchangeable working correlation structure to handle repeated observations over time for each DL. The main variable of interest was time to reflect the annual progression of each lesion. Models were adjusted for sex, HLA-B27 status, BMI, smoking (ever vs never) and job type (no professional activity, white or blue collar) at baseline and biologic therapy exposure (ever vs never) during the 10Y period. Annual change percentage or β-coefficients and 95% confidence intervals (95%CI) were reported.

Results: DLs were available for 330 patients (mean age [SD] 34.5 [8.6] years; 47% men) (Figure 1). There was a mean (SD) of 1.6 (2.5) DLs per patient at baseline on radiographs; this number increased to 3.4 (3.9) at 10Y. On MRI, there was a mean of 7.5 (5.5) DLs per patient at baseline and 11.0 (7.1) at 10Y . A significant progression was mainly detected on radiographs for osteophytes (annual change=2.2%, 95%CI: 1.9-2.7), disc height loss (1.4%, 0.9-1.8), and facet joint osteoarthritis (1.3%, 0.9-1.7). The same trend was detected on MRI for disc protrusion (1.1%, 0.6-1.6), Modic type I (1.0%, 0.7-1.3) and II (0.9%, 0.7-1.2) (Table 1). We observed a statistically significant increase in the number of DLs on radiographs (β=1.8, 95%CI: 1.5-2.1) and MRI (4.2, 3.5-4.8). Factors associated with DLs progression in both imaging modalities were increasing BMI (0.2, 0.1-0.2 on radiographs; 0.4, 0.3-0.4 on MRI) and biologic exposure (0.4, 0.1-0.7 on radiographs; 0.9, 0.3-1.5 on MRI) (Table 2).

Conclusion: In an inception cohort of axSpA degenerative spinal lesions, though common, progress very slowly over 10Y, both on radiographs and MRI. However, this progression appears to be faster in patients with a higher BMI and those exposed to bDMARDs, which likely indicates a more severe form of axSpA.

Reference: 1. de Bruin F et al. RMD Open. 2018;4(1):e000657.

Supporting image 1

Sagittal STIR images of the cervicothoracic (A, B) and lumbar (C, D) spine at baseline (A, C) and after 10 years of follow-up (B,D).
Pannels A and B: Full arrows indicate a decrease in the height of the intervertebral disc spaces at multiple levels with decrease of the signal of the discs Th1-Th4, Th5-Th6 and Th7-Th8 (from grade II to grade IV of Pfirrmann classification).
Pannels C and D: The arrows indicate progressive disc degeneration at all lumbar levels with discs L1-L5 from grade III to grade IV of Pfirrmann classification (full arrows), and L5-S1 from grade II to grade III of Pfirrmann classification (dotted arrow). Circles indicate disc protrusions.
Disc degeneration was scored on a five-point scale (Pfirrmann classification), combining signal loss and loss of height of the intervertebral discs on STIR images, and was defined as a disc with a Pfirrmann classification >2.

Supporting image 2

* Percentage change per year estimated used generalised estimating equation (GEE) models, considering individual reader data and exchangeable working correlation structure, adjusted for sex, body mass index, HLA-B27 status, tobacco use, job type and biological disease-modifying antirheumatic drugs exposure.
Loss of disc height was defined as narrowing of the disc space in comparison with two adjacent (healthy) discs. Osteophytes were described by reactive bone hypertrophy, seen as bony spurs arising from the vertebral body close to the vertebral endplate in a horizontal configuration (maximum of 45-degree angle with the endplate). Facet joint osteoarthritis was defined as sclerotic joint surfaces and osteophyte formation. Schmorl’s nodes were defined as a radiolucent contour defect of the vertebral endplate with sclerotic margins. Sclerosis was defined by an increased bone density and calcification adjacent to the vertebral endplates. Spondylolisthesis was defined as the slippage of one vertebral body with respect to the adjacent vertebral body.
Disc degeneration was scored on a five-point scale (Pfirrmann classification), combining signal loss and loss of height of the intervertebral discs on STIR images. The high-intensity zone, indicating an annular tear or fissure, is seen as an area of high signal intensity located in the posterior annulus fibrosis on STIR images. We considered bulging of a disc as either protrusion or extrusion; the distinction is based on whether the maximal diameter in any direction is at the base of the displacement (protrusion) or not (extrusion). Schmorl’s nodes were defined as an indentation of the (cranial or caudal) endplate with herniation of intervertebral disc material into the vertebra, with or without oedema. We used the Modic classification to assess degenerative lesions of the vertebral endplates. This is a three-point scale with type I defined as bone marrow oedema, type II is described as fatty changes and type III as sclerotic changes. Canal stenosis was defined as reduction of the anterior–posterior diameter of the spinal canal with compression on the spinal cord (at cervical and thoracic level) or as contact between the nerve root and disc material with obliteration of perineural intraforaminal fat or compression of the nerve root (at lumbar level). Spondylolisthesis was defined as the slippage of one vertebral body with respect to the adjacent vertebral body. Scheuermann’s disease was defined as abnormal and excessive curvature of the spin with anterior wedging of greater than or equal to 5 degrees in 3 or more adjacent vertebral bodies.Facet joint osteoarthritis was defined as sclerotic joint surfaces and osteophyte formation.
Bold characters indicate significant values. MRI: magnetic resonance imaging; 95%CI: 95% confidence interval.

Supporting image 3

* β coefficients associated with annual progression estimated used generalised estimating equation (GEE) models, considering individual reader data and exchangeable working correlation structure.
Bold characters indicate significant values. MRI: magnetic resonance imaging; 95%CI: 95% confidence interval; BMI: body mass index; HLA: human leucocyte antigen; bDMARDs: biological disease-modifying antirheumatic drugs.


Disclosures: L. Pina Vegas: Novartis, 5; S. Ramiro: AbbVie, 1, 2, 5, 6, Alfasigma, 1, 2, 5, Galapagos, 1, 2, 5, Lilly, 1, 2, 6, MSD, 2, 5, 6, Novartis, 1, 2, 5, 6, Pfizer, 1, 2, 5, 6, UCB, 1, 2, 5, 6; M. van Lunteren: None; D. Loeuille: None; E. Newsum: None; C. Morizot: None; F. van Gaalen: AbbVie, 12, Personal fees, BMS, 12, Personal fees, Eli Lilly, 12, Personal fees, Jacobus Stichting, 5, MSD, 12, Personal fees, Novartis, 2, 5, Stichting ASAS, 5, Stichting Vrienden van Sole Mio, 5, UCB Pharma, 5; A. SARAUX: Abbvie, BMS, Galapagos, Lilly, Novartis, Nordic, Pfizer, Roche-Chugai, Sanofi, UCB, 6, Abbvie, Bms, Lilly, Novartis, 5; P. Claudepierre: AbbVie, 2, 6, Amgen, 2, Biogen, 2, Celltrion, 2, Galapagos, 2, Janssen, 2, 6, Lilly, 2, 6, MSD, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, UCB, 2; A. Feydy: None; D. van der Heijde: AbbVie, 2, ArgenX, 2, BMS, 2, Eli Lilly, 2, Galapagos, 2, GSK, 2, Imaging Rheumatology BV, 3, Janssen, 2, Novartis, 2, Pfizer, 2, Takeda, 2, UCB Pharma, 2; M. Reijnierse: ASAS, 2, ISS, 5.

To cite this abstract in AMA style:

Pina Vegas L, Ramiro S, van Lunteren M, Loeuille D, Newsum E, Morizot C, van Gaalen F, SARAUX A, Claudepierre P, Feydy A, van der Heijde D, Reijnierse M. Factors Associated with the Evolution of Degenerative Spinal Lesions in Axial Spondyloarthritis: 10-Year Follow-up of the DESIR Cohort [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/factors-associated-with-the-evolution-of-degenerative-spinal-lesions-in-axial-spondyloarthritis-10-year-follow-up-of-the-desir-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-the-evolution-of-degenerative-spinal-lesions-in-axial-spondyloarthritis-10-year-follow-up-of-the-desir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology